Raymond James Financial
KZIA

Raymond James Financial’s Kazia Therapeutics KZIA Stock Holding History

Raymond James Financial’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Buy
22,599
+6,850
+43% +$83.4K ﹤0.01% 4783
2026
Q1 		$117K Buy
+15,749
New +$110K ﹤0.01% 5004

Other funds holding KZIA

BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Raymond James Financial's KZIA Position: Q2 2026 in Review

Raymond James Financial increased its Kazia Therapeutics (KZIA) stake by 43% in Q2 2026, buying an estimated $83.4K and bringing the position to 22,599 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #4783.

Raymond James Financial first reported a position in KZIA in Q1 2026 and has held it in 2 quarters since. 35 funds tracked by Wall St. Rank hold KZIA as of Q2 2026.

  • Raymond James Financial held 22,599 shares of Kazia Therapeutics worth $318K as of Q2 2026.
  • Raymond James Financial bought 6,850 Kazia Therapeutics shares in Q2 2026, an estimated $83.4K.
  • Kazia Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4783 holding.
  • Raymond James Financial first reported a position in Kazia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 35 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.